[1] Shirali A, Pazhayattil GS .Drug-induced impairment of renal function[J].International Journal of Nephrology and Renovascular Disease, 2014, 12(7):457-468. [2] 裴小华, 赵卫红. 老年人肾功能评估现状与进展[J]. 中华老年多器官疾病杂志, 2013, 12(1):77-80. [3] Launayvacher V, Chatelut E, Lichtman SM, et al.Renal insuff-iciency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations[J]. European Journal of Cancer Supplements, 2007, 5(4):1314. [4] Arany I, Safirstein RL.Cisplatin nephrotoxicity[J]. Seminars in Nephrology, 2003, 23(5): 460-464. [5] 银正民, 官成浓, 黄纳新,等. 高剂量与分割剂量顺铂的EP方案治疗晚期非小细胞肺癌(附72例分析)[J]. 中华肿瘤杂志,1995,17(3): 226-228. [6] 李燕, 沈琳, 李洁, 等. 分次小剂量顺铂联合化疗对胃癌患者肾功能的影响[J]. 癌症, 2007, 26(12): 1354-1356. [7] Kintzel PE, Dorr RT.Anticancer drug renal toxicity and elimi-nation: dosing guidelines for altered renal function[J]. Cancer Treatment Reviews, 1995, 21(1):0-64. [8] Launay-Vacher V, Rey JB, Isnard-Bagnis C, et al.Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care[J]. Cancer Chemotherapy and Pharmacology,2008, 61(6):903-909. [9] Lehane D, Winston A, Gray R, et al.The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity[J]. International Journal of Radiation Oncology Biology Physics, 1979, 5(8):1393-1399. [10] Alsarraf M, Fletcher W, Oishi N, et al.Cisplatin hydration with and without mannitol diuresis in refractory disseminated malig-nant melanoma: a southwest oncology group study[J]. Cancer Treat Rep, 1982, 66(1):31-35. [11] Santoso J T, Lucci J A, Coleman R L, et al.Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a rand-omized trial[J]. Cancer Chemotherapy and Pharmacology, 2003,52(1):13-18. [12] Hazarika M, White RM, Johnson JR, et al.FDA drug approval summaries: Pemetrexed (Alimta )[J]. Oncologist, 2004, 9(5):482-488. [13] Rinaldi D A, Kuhn JG, Burris HA, et al.A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation[J]. Cancer Chemotherapy and Pharmacology, 1999, 44(5):372-380. [14] Kono M, Sakata Y, Sugawara T, et al.Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function[J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2014, 41(13):2587-2590. [15] ChenCY, Lin JW, Huang JW, et al. Estimated Creatinine Clear-ance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. Clinical Lung Cancer, 2015, 16(6):e131-e140. [16] Funaguchi N, Nakajima Y, Kaito D, et al.[Analysis of Pemet-rexed Monotherapy in Advanced Non-Small Cell Lung CancerPatients with Impaired Renal Function[J]. Gan to Kagaku Ryoho Cancer & Chemotherapy, 2015, 42(6):705-708. [17] Jordan H, Craig V, Michael S, et al.Safety of dose-reduced pemetrexed in patients with renal insufficiency[J]. Journal of Oncology Pharmacy Practice, 2019, 25(5):1125-1129. [18] Zhu X, Wu S, Dahut W L, et al.Risks of Proteinuria and Hyper-tension With Bevacizumab, an Antibody Against Vascular Endo-thelial Growth Factor: Systematic Review and Meta-Analysis[J].American Journal of Kidney Diseases, 2007, 49(2):186-193. [19] Shord SS, Bressler LR, Tiernery LA, et al.Understand-ing and managing the possible adverse effects associated with bevac-izumab[J]. Am J Health Syst Pharm,2009,66(11):999-1013. [20] Miller KD, Chap LI, Holmes FA, et al.Randomized phase III trial of capecitabine compared with bevacizumab plus capecita- bine in patients with previously treated metastatic breast cancer.J Clin Oncol,2005,23(4):792-799. [21] Advani A, Kelly D J, Advani S L, et al.Role of VEGF in main-taining renal structure and function under normotensive and hypertensive conditions[J]. Proceedings of the National Academy of Sciences, 2007, 104(36):14448-14453. [22] Mohammed NM, Mahfouz A, Achkar K, et al.Contrast-induced nephropathy[J]. HeartViews,2013,14(3):106-116. [23] Solomon R.The role of osmolality in the incidence of contrast-induced nephropathy: A systematic review of angiographic contrast media in high risk patients[J]. Kidney International,2005, 68(5):2256-2263. [24] Dussol B.A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients[J]. Neph-rology Dialysis Transplantation, 2006, 21(8):2120-2126. [25] Trivedi H, Foley WD.Contrast-induced nephropathy after asecond contrast exposure[J]. Renal Failure, 2010, 32(7):796-801.[26] Abujudeh HH, Gee MS , Kaewlai R . In Emergency Situations,Should Serum Creatinine Be Checked in All Patients Before Performing Second Contrast CT Examinations Within 24 Hours?[J].Journal of the American College of Radiology, 2009, 6(4):268-273. [27] Owen R J, Hiremath S, Myers A, et al.Canadian Association of Radiologists Consensus Guidelines for the Prevention of Contrast-Induced Nephropathy: Update 2012[J]. Canadian Association of Radiologists Journal, 2014, 65(2):96-105. |